Bank of New York Mellon’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-231,043
| Closed | -$4.95M | – | 4319 |
|
|
2026
Q1 | $4.95M | Buy |
231,043
+19,497
| +9% | +$275K | ﹤0.01% | 2321 |
|
|
2025
Q4 | $1.97M | Sell |
211,546
-94,634
| -31% | -$791K | ﹤0.01% | 2842 |
|
|
2025
Q3 | $2.16M | Sell |
306,180
-1,673
| -0.5% | -$11.5K | ﹤0.01% | 2762 |
|
|
2025
Q2 | $2M | Buy |
307,853
+59,473
| +24% | +$409K | ﹤0.01% | 2747 |
|
|
2025
Q1 | $1.97M | Buy |
248,380
+3,551
| +1% | +$38.3K | ﹤0.01% | 2698 |
|
|
2024
Q4 | $3.1M | Buy |
244,829
+74,091
| +43% | +$1.03M | ﹤0.01% | 2540 |
|
|
2024
Q3 | $2.38M | Sell |
170,738
-37,658
| -18% | -$537K | ﹤0.01% | 2669 |
|
|
2024
Q2 | $2.87M | Sell |
208,396
-6,987
| -3% | -$102K | ﹤0.01% | 2598 |
|
|
2024
Q1 | $3.56M | Sell |
215,383
-18,815
| -8% | -$282K | ﹤0.01% | 2486 |
|
|
2023
Q4 | $3.42M | Buy |
234,198
+13,902
| +6% | +$169K | ﹤0.01% | 2563 |
|
|
2023
Q3 | $2.7M | Buy |
220,296
+40,387
| +22% | +$527K | ﹤0.01% | 2639 |
|
|
2023
Q2 | $2.15M | Buy |
179,909
+68,278
| +61% | +$892K | ﹤0.01% | 2794 |
|
|
2023
Q1 | $1.49M | Buy |
111,631
+11,130
| +11% | +$217K | ﹤0.01% | 2953 |
|
|
2022
Q4 | $2.16M | Sell |
100,501
-1,722
| -2% | -$35.3K | ﹤0.01% | 2821 |
|
|
2022
Q3 | $2.05M | Buy |
102,223
+38,681
| +61% | +$823K | ﹤0.01% | 2836 |
|
|
2022
Q2 | $1.14M | Buy |
63,542
+6,052
| +11% | +$62.5K | ﹤0.01% | 3154 |
|
|
2022
Q1 | $570K | Buy |
57,490
+25,250
| +78% | +$334K | ﹤0.01% | 3632 |
|
|
2021
Q4 | $543K | Buy |
32,240
+5,445
| +20% | +$112K | ﹤0.01% | 3757 |
|
|
2021
Q3 | $635K | Buy |
+26,795
| New | +$642K | ﹤0.01% | 3663 |
|
Other funds holding DAWN
Bank of New York Mellon's DAWN Position: Q2 2026 in Review
Bank of New York Mellon sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 231,043 shares — an estimated $4.95M sold.
Bank of New York Mellon first reported a position in DAWN in Q3 2021 and held it in 19 quarters. The position peaked at $4.95M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Bank of New York Mellon reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Bank of New York Mellon sold 231,043 Day One Biopharmaceuticals shares in Q2 2026, an estimated $4.95M.
- Bank of New York Mellon first reported a position in Day One Biopharmaceuticals in Q3 2021 and held it in 19 quarters.
- Bank of New York Mellon's Day One Biopharmaceuticals position peaked at $4.95M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.